New hope for lung cancer patients who stop responding to targeted drugs
NCT ID NCT05184712
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding the experimental drug AK112 (ivonescimab) to standard chemotherapy can help people with a certain type of advanced lung cancer (EGFR-mutant non-squamous NSCLC) whose cancer has worsened after targeted therapy. About 322 participants will receive either AK112 plus chemo or a placebo plus chemo. The main goal is to see if the combination delays cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ivonescimab (AK112) combined with pemetrexed and carboplatin
- What this could lead to
- If successful, this could offer a new treatment option for people with a specific type of lung cancer that has stopped responding to standard targeted therapy.
- What could go wrong
- This is a phase 3 trial, but results are not yet available. The drug combination may not improve survival or could cause significant side effects. It is only tested in a specific patient group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a novel drug combo outperform standard chemo for lung cancer?
- Can a Four-Drug cocktail shrink Hard-to-Treat lung tumors?
- New lung cancer drug aims to match Keytruda's success
- Targeted drug shows promise for Gene-Driven lung cancers
- Engineered virus plus immunotherapy aims to outperform chemo in advanced lung cancer
- New drug duo aims to tackle Hard-to-Treat cancers